SELECT: Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest

Sponsor
Medisch Spectrum Twente (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06048796
Collaborator
Rijnstate Hospital (Other), University of Twente (Other)
40
2
2
36
20
0.6

Study Details

Study Description

Brief Summary

The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (< 12 h) favourable EEG pattern (indicating no or mild postanoxic encephalopathy).

Condition or Disease Intervention/Treatment Phase
  • Other: Early cessation of sedation and TTM
N/A

Detailed Description

Comatose patients after cardiac arrest are treated on intensive care units with sedative medication, targeted temperature management (TTM), mechanical ventilation, and hemodynamic support. Despite substantial variation in the severity of the encephalopathy and even lack of unequivocal evidence of efficacy of sedation and TTM, all patients receive standard treatment. The severity of the postanoxic encephalopathy can reliably be assessed with the electroencephalogram (EEG). A continuous EEG pattern within the first 12 hours after cardiac arrest ("favorable EEG") is strongly associated with a good neurological outcome and reflects a very mild or transient encephalopathy. The investigators hypothesize that this subgroup of patients, with a favorable EEG will not benefit from prolonged sedation and TTM.

The objective of this study is to estimate the feasibility and safety of early weaning from ICU treatment in patients after cardiac arrest and an early (< 12 h) favourable EEG pattern. The study design is a cluster randomized crossover design with two treatment arms. The intervention contrast will be early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate (intervention group) vs. standard care, including sedation and TTM for at least 24-48 hours (control group). The investigators will include forty adult patients admitted to the ICU with postanoxic encephalopathy after cardiac arrest and an early (<12 hours) favorable EEG pattern.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A cluster randomized crossover design with two treatment arms (early cessation from sedation and TTM vs standard care).A cluster randomized crossover design with two treatment arms (early cessation from sedation and TTM vs standard care).
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest: a Feasibility and Safety Study
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2026
Anticipated Study Completion Date :
Oct 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Early cessation of sedation and TTM

Early cessation of sedation and targeted temperature management (TTM), with subsequent weaning from mechanical ventilation if appropriate (intervention group).

Other: Early cessation of sedation and TTM
Early cessation of sedation and TTM, with subsequent weaning from mechanical ventilation if appropriate

No Intervention: Standard Care

Standard care, including sedation and targeted temperature management (TTM) for at least 24-48 hours (control group).

Outcome Measures

Primary Outcome Measures

  1. Mechanical ventilation time in hours [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

Secondary Outcome Measures

  1. Length of ICU stay [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

  2. Total sedation time [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

  3. Need for re-intubation [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

  4. Need for restarting sedation [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

  5. Number of serious adverse events (SAEs) [at 3 and 6 months]

  6. Mortality [at 30 days, 3 months and 6 months]

  7. Complications during intensive care admission [During the complete ICU admission (from admission to the ICU until discharge from the ICU, up to 30 days).]

    Number of pneumonia, sepsis (according to sepsis 3 criteria), bleeding (any cause), cardiac arrhythmia (any associated with hemodynamic compromise), new cardiac arrest and thrombopenia

  8. Neurological outcome measured at the Extended Glasgow Outcome Scale (GOSE) [at 3 and 6 months]

    The CPC ranges from 1 to 8, with higher scores meaning better neurological outcome.

  9. Neurological outcome measured at the Cerebral Performance Category (CPC) [at 3 and 6 months]

    The CPC ranges from 1 to 5, with higher scores meaning worse neurological outcome.

  10. Cognitive functioning [at 3 and 6 months]

    Montreal Cognitive Assessment (MOCA) score via videoconference. The MOCA ranges from 0 to 30, with higher scores meaning better cognitive functioning.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.

  • Age 18 years or older.

  • Continuous EEG measurement started within 12 hours after cardiac arrest.

  • Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).

  • Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.

  • Written informed consent (deferred).

Exclusion Criteria:
  • A known history of another medical condition with limited life expectancy (<6 months).

  • Any progressive brain illness, such as a brain tumour or neurodegenerative disease.

  • Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.

  • Reason other than neurological condition to continue sedation and/or ventilation.

  • Follow-up impossible due to logistic reasons.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rijnstate hospital Arnhem Netherlands
2 Medisch Spectrum Twente Enschede Netherlands

Sponsors and Collaborators

  • Medisch Spectrum Twente
  • Rijnstate Hospital
  • University of Twente

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Job van der Palen, Clinical epidemiologist and professor, Medisch Spectrum Twente
ClinicalTrials.gov Identifier:
NCT06048796
Other Study ID Numbers:
  • SELECT
  • NL84714.100.23
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Job van der Palen, Clinical epidemiologist and professor, Medisch Spectrum Twente
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023